Skip to main content Skip to section navigation Skip to footer
French

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Clinical Pipeline
    • GTX-104
    • GTX-102
    • GTX-101
  • Investor Relations
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Newsroom
  • Careers
  • Contact
  • French

Press Releases

Investor Relations

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • Analyst Coverage
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Sep 6, 2023

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 11, 2023

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Aug 9, 2023

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 10, 2023

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 7, 2023

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jul 5, 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 23, 2023

Acasti Announces Appointment of New Scientific Advisory Board Members

Jun 22, 2023

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

May 8, 2023
rss_feed News RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...26
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2023 Acasti Pharma Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap